Clinical trials: Moderate to Severe Asthma
Asthma
Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma
The aim of this trial is to evaluate the safety and efficacy of 2.5 and 5 µg tiotropium over a 52-week treatment period as compared to placebo.
- Trial name
- NCT01340209
- Testing
- Tiotropium Respimat
- Where
- 55 sites in Japan
- Volunteers
- 285 people
- Sponsor
- Boehringer Ingelheim
Asthma
A Study of Itolizumab (EQ001) to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity in Uncontrolled Asthma
This is a multi-center study to evaluate the safety, tolerability, PK, PD, and clinical activity of itolizumab (EQ001) in subjects with moderate-to-severe asthma.
- Trial name
- EQUIP (NCT04007198)
- Testing
- EQ001
- Where
- 13 sites in Australia, New Zealand
- Volunteers
- 18 people
- Sponsor
- Biocon Limited
Allergic Asthma
Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients
This is a multicenter, randomized, masked, active and placebo controlled, Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetics of LP-003 injection in adult patients with moderate to severe persistent…
- Trial name
- NCT07342803
- Testing
- LP-003 Injection, Omalizumab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Longbio Pharma
Asthma
Study to Evaluate the Safety and Efficacy of CAT-354
This is a Phase 2a, randomized, double-blind, placebo-controlled, parallel-arm study to evaluate the efficacy and safety of 3 subcutaneous (SC) treatment regimens of CAT-354 in adult subjects with uncontrolled…
- Trial name
- NCT00873860
- Testing
- CAT-354 150 mg, CAT-354 300 mg, CAT-354 600 mg
- Where
- 57 sites in Bulgaria, Germany and 3 more
- Volunteers
- 357 people
- Sponsor
- MedImmune LLC
Moderate to Severe Asthma
A Phase Ib Study of RC1416 Injection
This is a Phase Ib study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RC1416 injection in patients with moderate to severe asthma.
- Trial name
- NCT06911866
- Testing
- RC1416
- Where
- 16 sites in China
- Volunteers
- 40 people
- Sponsor
- Nanjing RegeneCore Biotech Co., Ltd.
Eosinophilic Asthma
AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma
This clinical trial aims to investigate patients with poorly controlled, moderate to severe eosinophilic asthma. The main questions it seeks to answer are 1.
- Trial name
- NCT05985694
- Testing
- AD17002
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Advagene Biopharma Co. Ltd.
Asthma
Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma
This study was designed to assess the safety of indacaterol (300 µg and 600 µg (2 x 300 μg capsules) once daily [od]), compared with salmeterol (50 μg twice a day [b.i.d.]), over 26 weeks, in patients with moderate to severe…
- Trial name
- NCT00529529
- Testing
- Indacaterol 300 μg, Salmeterol 50 μg
- Where
- 126 sites in United States, Argentina and 10 more
- Volunteers
- 805 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
A Study to Assess the Effects of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Mild, Moderate or Severe Hepatic Impairment.
In relation to their severity, hepatic diseases can significantly modify drug absorption and disposition and consequently can interfere with drug efficacy and/or produce toxicity.
- Trial name
- NCT01266941
- Testing
- Inhaled FF 200mcg/GW642444M 25mcg
- Where
- 3 sites in Czechia, Slovakia
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
OSA
Continuous Positive Airway Pressure Use in Asthma With Moderate to Severe Obstructive Sleep Apnea Patients
Obstructive sleep apnea syndrome (OSAS) and asthma are both common disorders in Hong Kong, with prevalence of at least 4% among the middle-aged male Hong Kong (HK) Chinese populations and 7.2% in young adults respectively.
- Trial name
- OSA (NCT01383564)
- Testing
- CPAP group, non CPAP group
- Where
- China
- Volunteers
- 101 people
- Sponsor
- Chinese University of Hong Kong
ALLERGIC ASTHMA
A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy
The researcher proposes to assess levels of sputum inflammatory markers (eosinophils, eosinophil cationic protein (ECP), neutrophils IL-8) before and while on anti-IgE therapy in a pediatric population of moderate to severe…
- Trial name
- NCT00283504
- Testing
- ANTI-IGE THERAPY (XOLAIR)
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of The King's Daughters
Asthma
Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe Asthma Patients
This study will assess the safety and tolerability of long-term treatment with omalizumab plus current asthma therapy in patients who participated in and successfully completed the treatment period of study CIGE025IA04E1.
- Trial name
- NCT00482508
- Testing
- Omalizumab
- Volunteers
- 95 people
- Sponsor
- Novartis
Asthma
New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) in Patients With Asthma
The purpose of this study is to evaluate the long-term safety of the fixed combination asthma drug FlutiForm HFA MDI (containing fluticasone propionate and formoterol fumarate) in adult and adolescent patients with mild to…
- Trial name
- NCT00394121
- Testing
- Fluticasone propionate/formoterol fumarate
- Where
- 28 sites in Germany, Hungary and 3 more
- Volunteers
- 400 people
- Sponsor
- SkyePharma AG
Moderate to Severe Asthma
CHEST: A Collaboration With Community HEalth Centers to Implement SmarT for Asthma
Purpose: This study aims to improve asthma care by helping clinicians at community health centers prescribe a guideline-recommended treatment called SMART (Single Maintenance and Reliever Therapy).
- Trial name
- CHEST (NCT07241117)
- Testing
- Implementation bundle
- Where
- 7 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Washington University School of Medicine
Asthma
An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma
Primary Objective: To evaluate the efficacy of different doses and regimens of dupilumab in participants with moderate to severe uncontrolled asthma.
- Trial name
- NCT01854047
- Testing
- Dupilumab, ICS/LABA therapy, Salbutamol/albuterol
- Where
- 201 sites in United States, Argentina and 14 more
- Volunteers
- 776 people
- Sponsor
- Sanofi
Moderate to Severe Asthma
Phase I Assessment of Hypertonic Saline in Moderate to Severe Asthmatics
Purpose: To determine if inhaled hypertonic saline (HS) accelerates airway mucociliary clearance (MCC) in well-controlled moderate to severe asthmatics.
- Trial name
- NCT03556683
- Testing
- 3% Hypertonic Saline, 7% Hypertonic Saline, Salbutamol
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of North Carolina, Chapel Hill
Asthma
Fish Oil to Prevent Asthma Exacerbations in Patients With ALOX5 Polymorphisms
This is a clinical study that is designed to study the effects of the supplemental intake of enriched omega-3 polyunsaturated fatty acids (fish oil) in patients with moderate to severe asthma.
- Trial name
- NCT00621829
- Testing
- EPA enriched fish oils
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, Davis
Asthma
Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants
Primary Objective: To evaluate the effects of SAR440340 with or without dupilumab, compared to placebo, on reducing the incidence of "loss of asthma control" (LOAC) events.
- Trial name
- NCT03387852
- Testing
- SAR440340, Dupilumab, Fluticasone or Fluticasone/salmeterol combination
- Where
- 71 sites in United States, Argentina and 6 more
- Volunteers
- 296 people
- Sponsor
- Sanofi
Asthma
A Study of RO5036505 in Patients With Moderate to Severe Asthma
This randomized, double-blind, placebo-controlled study will evaluate the efficacy, safety and tolerability of RO5036505 in patients with inadequately controlled moderate to severe asthma.
- Trial name
- NCT00967590
- Testing
- RO5036505
- Where
- 16 sites in United States, United Kingdom
- Sponsor
- Hoffmann-La Roche
Moderate to Severe Allergic Asthma
A Clinical Study of Omalizumab in the Treatment of Allergic Asthma(ESSENCE)
Allergic asthma being the most widespread and easily identifiable phenotype, accounting for 60-80% of cases.Previous studies have reported that nearly 90% of patients with severe asthma were cases of allergic asthma, in which…
- Trial name
- ESSENCE (NCT06348407)
- Testing
- IgE monoclonal antibody
- Where
- China
- Volunteers
- 300 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Asthma
Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe Asthma
This is a parallel, treatment, Phase 2, double-blind, 2 arm, 12-week Proof of Concept (PoC) study with 2 staggered cohorts (2 arms in each cohort) that is designed to assess the efficacy, safety, and tolerability of rilzabrutinib…
- Trial name
- NCT05104892
- Testing
- Rilzabrutinib
- Where
- 51 sites in Argentina, Bulgaria and 11 more
- Volunteers
- 196 people
- Sponsor
- Sanofi